The estimated Net Worth of Colin Hill is at least $286 ezer dollars as of 21 September 2020. Mr. Hill owns over 1,722 units of HeartBeam Inc stock worth over $31,874 and over the last 9 years he sold BEAT stock worth over $53,864. In addition, he makes $200,048 as Independent Director at HeartBeam Inc.
Sign up
Mr. Hill BEAT stock SEC Form 4 insiders trading
Colin has made over 1 trades of the HeartBeam Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,722 units of BEAT stock worth $53,864 on 21 September 2020.
The largest trade he's ever made was selling 1,722 units of HeartBeam Inc stock on 21 September 2020 worth over $53,864. On average, Colin trades about 144 units every 0 days since 2016. As of 21 September 2020 he still owns at least 14,166 units of HeartBeam Inc stock.
You can see the complete history of Mr. Hill stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Colin Hill biography
Colin Hill serves as Independent Director of the Company. Mr. Hill is a leading voice in healthcare technology and precision medicine and brings impressive leadership experience in commercializing machine learning technologies in the biopharmaceutical and managed care industries. He co-founded GNS Healthcare in 2000 and has since served as Chairman and Chief Executive Officer. Mr. Hill sits on board of PPD, a leading global contract research organization. He is also a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation (501(c)(3)) dedicated to the advancement of personalized medicine. In 2016, he was appointed by Massachusetts Governor Charlie Baker to the Massachusetts Digital Health Council. Mr. Hill was a founding member of the board of directors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease (acquired by Baxter in 2014). He was the founding chairman of O’Reilly Media’s Strata Rx in 2012, the first healthcare big data conference in the industry. In 2004, Mr. Hill was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35.
What is the salary of Colin Hill?
As the Independent Director of HeartBeam Inc, the total compensation of Colin Hill at HeartBeam Inc is $200,048. There are 10 executives at HeartBeam Inc getting paid more, with Joseph Capper having the highest compensation of $4,133,160.
How old is Colin Hill?
Colin Hill is 47, he's been the Independent Director of HeartBeam Inc since 2016. There are 16 older and 1 younger executives at HeartBeam Inc. The oldest executive at HeartBeam Inc is Robert Rubin, 74, who is the Independent Director.
What's Colin Hill's mailing address?
Colin's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.
Insiders trading at HeartBeam Inc
Over the last 11 years, insiders at HeartBeam Inc have traded over $23,124,978 worth of HeartBeam Inc stock and bought 31,500 units worth $221,145 . The most active insiders traders include Joseph H Capper, Heather C Getz és Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of $55,046. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth $3,917.
What does HeartBeam Inc do?
heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.
What does HeartBeam Inc's logo look like?
Complete history of Mr. Hill stock trades at HeartBeam Inc, Fulcrum Therapeutics Inc és PPD Inc
HeartBeam Inc executives and stock owners
HeartBeam Inc executives and other stock owners filed with the SEC include:
-
Joseph Capper,
President, Chief Executive Officer, Director -
Heather Getz,
Chief Financial Officer, Executive Vice President, Chief Administrative Officer -
Fred Broadway,
President, BioTel Heart -
Daniel Wisniewski,
Senior Vice President - Technical Operations -
Kirk Gorman,
Independent Chairman of the Board -
Rebecca Rimel,
Independent Director -
Anthony Conti,
Independent Director -
Joseph Frick,
Independent Director -
Stephan Rietiker,
Director -
Robert Rubin,
Independent Director -
Colin Hill,
Independent Director -
Tiffany Olson,
Independent Director -
Laura Dietch,
Independent Director -
Dr. Branislav Vajdic Ph.D.,
Founder, CEO & Director -
Richard D. Brounstein,
Chief Financial Officer -
Manish Wadhwa,
Chief Medical Officer -
Andrei Stoica,
Chief Technology Officer -
Dr. Peter J. Fitzgerald FACC, M.D., Ph.D.,
Chief Medical Officer -
Ken Persen,
Chief Technology Officer -
Dr. Jon Hunt Ph.D.,
Exec. VP & Chief Bus. Officer -
Alexei Shvilkin M.D.,
Chief Medical Officer -
Dr. Dorin Panescu Ph.D.,
Chief Technical Officer -
Alan Baumel,
Chief Operating Officer -
Richard M. Ferrari,
Exec. Chairman -
George Hrenko,
Senior Vice President -
Stephen Rietiker,
Director -
Michael Geldart,
Senior Vice President -
Ronald A Ahrens,
Director -
Eric N Prystowsky,
Director -
Peter Ferola,
SVP & General Counsel -
Kenneth Warwick Iii Nelson,
Director -
Mark E Strome,
10% owner -
Michael R Jaff,
Director -
Willem Elfrink,
Director -
Marga Ortigas Wedekind,
Director -
Urioste George De,
Director -
Richard Ferrari,
Director -
Jon Patrick Hunt,
Chief Business Officer -
Richard Brounstein,
Chief Financial Officer -
Alan Baumel,
Chief Operating Officer -
Kenneth Harry Persen,
Chief Technology Officer -
Robert Paul Eno,
President -
Branislav Vajdic,
CHIEF EXECUTIVE OFFICER